Completed PHASE2 INTERVENTIONAL 2-arm NCT02540655

Efficacy and Safety Study of Stemchymal® in Polyglutamine Spinocerebellar Ataxia

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Single-Center Study to Evaluate the Safety and Efficacy of Stemchymal® Infusion for the Treatment of Polyglutamine Spinocerebellar Ataxia

Sponsor: Steminent Biotherapeutics Inc.

Conditions Cerebellar Ataxia

Interventions Excipients Stemchymal®

Updated 7 times since 2017 Last updated: Oct 26, 2022 Started: Sep 30, 2015 Primary completion: Feb 26, 2021 Completion: Feb 26, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Cerebellar Ataxia and is currently completed. Steminent Biotherapeutics Inc. leads this study, which shows 7 recorded versions since 2015 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Nov 2022 — Jul 2024 [monthly]

Completed PHASE2

Status: Unknown Status → Completed
Jan 2021 — Nov 2022 [monthly]

Unknown Status PHASE2
Nov 2018 — Jan 2021 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status

▶ Show 2 earlier versions

Jun 2018 — Nov 2018 [monthly]

Recruiting PHASE2
Jan 2017 — Jun 2018 [monthly]

Recruiting PHASE2

First recorded

Sep 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Steminent Biotherapeutics Inc.

Data source: Steminent Biotherapeutics Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Taipei, Taiwan